|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
| Pressure is increasing on today’s pharmaceutical industry to
implement more reliable and consistent safeguards against
mistakes in dispensing medication, whether from contamination,
mixing up drugs or inappropriate dosing. As a result,
pharmaceutical companies are turning to non-destructive testing
(NDT) techniques for product and packaging inspection.
A
number of these techniques have already been adopted, including
the use of optical, infra-red, ultrasound, vacuum decay and x-ray
inspection methods. Traditionally, these have primarily been used
for batch control through various batch sampling and inspection
strategies. However, there is increasing demand for in-line
inspection of all products, particularly where they have high
commercial value or involve high dosage levels.
Applications for in-line NDT of products are as varied as the
products themselves. Typical inspection scenarios may entail:
checking fill levels in bottles and tubs of drugs, in liquid, powder,
and even tablet forms; checking for missing tablets in blister packs;
detecting contaminants (such as metal or glass) in dressings; and
checking for correctly assembled devices. |
Read full article >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
 |

 |
Industry Events |
 |
DIA 4th Annual Clinical Forum & Exhibition
11-13 October 2010, Lisbon, Portugal
The DIA 4th Annual Clinical Forum provides access to sessions covering nine multidisciplinary themes, including Clinical Data Management/eClinical, Clinical Operations, Clinical Research, Peri- and Post Approval Studies, Drug Safety and Risk Management, Quality Assurance, Clinical Endpoints, e-Technology and Validation and Medical Information & Communications.
More info >> |
|
 |
News and Press Releases |
 |
Glycotope GMBH
Berlin, Germany – August 4, 2010
Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
More info >> |
|
|